Uganda’s battle against HIV/AIDS faces an unprecedented challenge following the recent suspension of key foreign aid from the United States, including funding from the U.S. Agency for International Development (USAID) and the President’s Emergency Plan for AIDS Relief (PEPFAR).
This decision threatens to disrupt life-saving antiretroviral (ARV) treatment for over a million HIV-positive Ugandans, raising urgent concerns about the country’s capacity to sustain its HIV/AIDS response without this vital support.
Since the early 2000s, Uganda has been at the forefront of the global fight against HIV/AIDS, earning international recognition for its aggressive prevention campaigns and robust treatment programs.
Central to this success has been the consistent support from international partners, especially the United States.
PEPFAR, launched in 2003, has been one of the largest contributors to Uganda’s HIV/AIDS efforts, investing over UGX 15 trillion into the country’s healthcare system.
This funding has supported everything from HIV testing and counseling to the procurement and distribution of ARV medications.
As of 2022, more than 1.3 million Ugandans living with HIV were receiving PEPFAR-supported ARV therapy, a critical lifeline for many.
Beyond providing treatment, USAID and PEPFAR have also funded prevention programs, maternal health services to prevent mother-to-child transmission, and community outreach initiatives that have educated millions about HIV/AIDS.
Thanks to these efforts, Uganda has seen a dramatic reduction in HIV prevalence, from 18% in the 1990s to 5.5% by 2021.
However, the recent decision to cut funding—triggered by concerns over governance and human rights issues—poses a significant threat to the sustainability of these achievements.
Maintaining ARV treatment for over a million people is both logistically and financially demanding. The cost of providing ARVs varies depending on the medication regimen and the patient’s condition. According to recent health sector reports:
First-line ARV treatment, which is the standard regimen for newly diagnosed individuals, costs between UGX 285,000 and UGX 475,000 per person per year.
For those who develop resistance to first-line drugs, second-line and third-line treatments are significantly more expensive, ranging from UGX 1.1 million to UGX 4.5 million per person annually.
Overall, Uganda spends more than UGX 937.5 billion annually on ARV drugs, healthcare personnel, laboratory services, and other related costs.
Prior to the funding cut, USAID and PEPFAR were covering up to 80% of these expenses. This leaves Uganda with a massive funding gap that, if not addressed promptly, could result in severe consequences for the country’s HIV-positive population.
The question of whether Uganda can independently finance its HIV/AIDS response is fraught with complexity. While the government has publicly committed to maintaining treatment programs, the reality is that Uganda’s healthcare budget is already under significant strain.
Uganda’s national health budget currently stands at approximately UGX 3.8 trillion. However, only a small fraction—less than 15%—is allocated to HIV/AIDS programs.
This allocation is insufficient to cover the full cost of ARV treatment for over a million people, especially given the rising demand for more expensive second- and third-line therapies as patients develop resistance.
Compounding the issue are other pressing health priorities. Uganda continues to grapple with high rates of malaria, tuberculosis, maternal mortality, and the lingering impacts of COVID-19. These competing demands on the healthcare budget make it difficult for the government to redirect sufficient resources to fill the funding gap left by USAID.
Furthermore, Uganda’s economy, while growing, faces its own set of challenges, including high public debt, inflation, and limited fiscal space. The government’s ability to raise additional funds through taxation or borrowing is constrained, making it unlikely that domestic resources alone will suffice to sustain the HIV/AIDS response at its current scale.
The most immediate and devastating consequence of the funding cut will be felt by the more than 1.3 million Ugandans currently on ARV therapy. Interruptions in treatment can lead to serious health complications, including the development of drug-resistant strains of HIV.
Once a patient develops resistance to first-line ARVs, they must transition to more expensive and complex second- or third-line treatments, which are not only costlier but also less widely available in Uganda.
Beyond the health implications for individuals, treatment disruptions pose a broader public health risk.
When people living with HIV are not on consistent treatment, their viral loads increase, making them more likely to transmit the virus to others.
This could lead to a resurgence in new HIV infections, undermining decades of progress in controlling the epidemic.
Vulnerable populations, including women, children, and key affected groups such as sex workers and men who have sex with men (MSM), are likely to be disproportionately affected. These groups already face barriers to accessing healthcare, and the loss of targeted programs funded by USAID could further marginalize them.
Community-based organizations that rely on USAID grants for prevention, counseling, and support services will also be hit hard. Many of these organizations operate on thin margins and may be forced to shut down without continued funding, leaving gaps in care and support for thousands of Ugandans.
The USAID funding cut has placed Uganda at a crossroads in its fight against HIV/AIDS. Without swift and decisive action, the country risks reversing the significant progress made over the past two decades.
The Ugandan government now faces the daunting task of finding alternative funding sources, reallocating budget priorities, and strengthening its healthcare infrastructure to ensure that those living with HIV continue to receive the treatment they need.
While Uganda has demonstrated resilience in the past, this challenge represents one of the most significant threats to its public health system. The coming months will be critical in determining whether the country can maintain its momentum in the fight against HIV/AIDS or face a devastating setback that could cost thousands of lives.
For now, over a million Ugandans living with HIV are left in limbo, anxiously hoping that a solution will be found before their life-saving medication runs out.
Join the Daily West Nile WhatsApp group now to never miss an update from us.Download Host Media Now from the Play Store to watch HostTV, listen to Host Radio
